These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 23362493)
1. Perampanel: a novel antiepileptic for the adjunctive treatment of refractory partial onset seizures. Owen RT Drugs Today (Barc); 2013 Jan; 49(1):23-31. PubMed ID: 23362493 [TBL] [Abstract][Full Text] [Related]
2. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878 [TBL] [Abstract][Full Text] [Related]
3. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures. Rektor I Expert Opin Pharmacother; 2013 Feb; 14(2):225-35. PubMed ID: 23259931 [TBL] [Abstract][Full Text] [Related]
4. Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Strzelczyk A; Willems LM; Willig S; Rosenow F; Bauer S Expert Rev Clin Pharmacol; 2015; 8(6):733-40. PubMed ID: 26436331 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel. Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857 [TBL] [Abstract][Full Text] [Related]
7. Perampanel: as adjunctive therapy in patients with partial-onset seizures. Plosker GL CNS Drugs; 2012 Dec; 26(12):1085-96. PubMed ID: 23179642 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001 [TBL] [Abstract][Full Text] [Related]
10. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety. Lagae L; Villanueva V; Meador KJ; Bagul M; Laurenza A; Kumar D; Yang H Epilepsia; 2016 Jul; 57(7):1120-9. PubMed ID: 27221398 [TBL] [Abstract][Full Text] [Related]
11. Perampanel: a new agent for adjunctive treatment of partial seizures. Faulkner MA Am J Health Syst Pharm; 2014 Feb; 71(3):191-8. PubMed ID: 24429011 [TBL] [Abstract][Full Text] [Related]
12. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials. Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895 [TBL] [Abstract][Full Text] [Related]
13. Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation. Schulze-Bonhage A Expert Opin Drug Metab Toxicol; 2015; 11(8):1329-37. PubMed ID: 26111428 [TBL] [Abstract][Full Text] [Related]
15. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Krauss GL; Serratosa JM; Villanueva V; Endziniene M; Hong Z; French J; Yang H; Squillacote D; Edwards HB; Zhu J; Laurenza A Neurology; 2012 May; 78(18):1408-15. PubMed ID: 22517103 [TBL] [Abstract][Full Text] [Related]
16. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307. Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701 [TBL] [Abstract][Full Text] [Related]
17. [Perampanel in treatment of refractory partial epilepsy in adolescents and adults: results of international multicenter randomized, double-blind, placebo-controlled phase III studies]. Belousova ED Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):32-8. PubMed ID: 25345628 [TBL] [Abstract][Full Text] [Related]
18. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Gidal BE; Ferry J; Majid O; Hussein Z Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853 [TBL] [Abstract][Full Text] [Related]
19. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy. Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies. Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]